TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An announcement from Santen Pharmaceutical Co ( (JP:4536) ) is now available.
Santen Pharmaceutical Co., Ltd. has completed the disposal of 57,909 treasury shares as part of its Post-delivery Type Performance-Linked Stock Remuneration Plan. This strategic move, based on a Board of Directors resolution, aims to align the interests of directors and corporate officers with company performance, potentially impacting the company’s operational efficiency and stakeholder value.
The most recent analyst rating on (JP:4536) stock is a Hold with a Yen1688.00 price target. To see the full list of analyst forecasts on Santen Pharmaceutical Co stock, see the JP:4536 Stock Forecast page.
More about Santen Pharmaceutical Co
Santen Pharmaceutical Co., Ltd. is a specialized company dedicated to eye health, providing products and services to patients, consumers, and medical professionals globally. With over 130 years of experience, Santen focuses on the research, development, manufacturing, and marketing of pharmaceutical products in the field of eye care, supporting the eye health of approximately 50 million people in more than 60 countries.
Average Trading Volume: 1,511,086
Technical Sentiment Signal: Hold
Current Market Cap: Yen510.8B
For a thorough assessment of 4536 stock, go to TipRanks’ Stock Analysis page.